Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA)

Web site

Administrative institutions

Université de Lille
CHU Lille

Presentation

Les axes de recherche développés au sein du Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) sont orientés vers les médicaments injectables, les dispositifs médicaux de perfusion et la modélisation biopharmaceutique et pharmacocinétique. L'unité est une équipe d'accueil (EA 7365) sous la tutelle de l'Université de Lille et du CHU de Lille.

Research teams

Innovation/évaluation des dispositifs médicaux de perfusion
Innovation/évaluation des médicaments injectables
Modélisation biopharmaceutique et pharmacocinétique

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Web site

Administrative institutions

Presentation

Research teams

Recent Submissions

Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study

Pulmonary hemorrhage in a neonate born to a woman with cystic fibrosis treated with targeted cystic fibrosis transmembrane conductance regulator modulator elexacaftor-tezacaftor-ivacaftor during pregnancy

IgE-mediated polysorbate 80 anaphylaxis after epidural injection of prednisolone

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.

Comparison of multiple cardiac signal acquisition technologies for heart rate variability analysis

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population.

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study

Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Web site

Administrative institutions

Presentation

Research teams

Recent Submissions

Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study ﻿

Pulmonary hemorrhage in a neonate born to a woman with cystic fibrosis treated with targeted cystic fibrosis transmembrane conductance regulator modulator elexacaftor-tezacaftor-ivacaftor during pregnancy ﻿

IgE-mediated polysorbate 80 anaphylaxis after epidural injection of prednisolone ﻿

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. ﻿

Comparison of multiple cardiac signal acquisition technologies for heart rate variability analysis ﻿

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study ﻿

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) ﻿

Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population. ﻿

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. ﻿

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study ﻿

Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study

Pulmonary hemorrhage in a neonate born to a woman with cystic fibrosis treated with targeted cystic fibrosis transmembrane conductance regulator modulator elexacaftor-tezacaftor-ivacaftor during pregnancy

IgE-mediated polysorbate 80 anaphylaxis after epidural injection of prednisolone

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial.

Comparison of multiple cardiac signal acquisition technologies for heart rate variability analysis

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population.

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study